International Journal of Frontiers in Biology and Pharmacy Research

An International, Peer reviewed, Open access Journal

ISSN: 2783-0454 (Online)

Background: Breast cancer is the secant-kind of carcinoma in women with higher incidence in Iraq. There are many prognostic and predictive factors used for management of the breast cancer. Serum levels of the cytokines may be utilized as a marker of immunity status and prognosis in CA breast.

Aims of the Study: Measuring the cytokines (IL-10 and IL-22) in breast cancer patients and association between the cytokines (IL-10 and IL-22 with stage and grade for breast cancer patient.

Materials and Methods: The case control study was conducted on 60 females with CA. Breast and 60 healthy controls group, the age both groups between 31-70 year, Groups patients with CA. Breast were referred to Middle Euphrates cancer center in Najaf and private the clinics for Physicians Oncology during the period November 2019 -October 2020. Measurement of cytokines (Interleukin-10 and Interleukin-22) by using Enzyme Linked Immunosorbent Assay.

Results: The showed a levels of IL-10 (186.3 ±39.5 pg/L) and IL-22 (187.1 ± 54.7ng/L) in patients of breast cancer higher than IL-10 (91.8 ± 30.6 pg/L) and IL-22 (82.6 ± 28.7 ng/L) in healthy control, and showed a high levels of IL-22 in advances stage and grade III. The showed non-significant in levels of IL-10 between four stages and three grade.

Conclusion: A significant elevation levels of IL-10 and IL-22 in breast cancer women groups comparison with control group, elevation significant of immunological levels of IL-22 in stages and grades of breast cancer women.